Thursday, March 19, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Europe’s COVID death toll could rise by hundreds of thousands

The COVID-19 pandemic could cost an extra 300,000 lives in Europe, according to a study of the number of people in 19 countries who have been neither infected nor vaccinated.

The study’s models also predict that the pandemic could lead to roughly one million hospitalizations in Europe, some of which would contribute to the projected death toll. But the authors of the analysis point out that their estimates are maximum numbers, which assume that all anti-infection restrictions are lifted and contacts between individuals have returned to their pre-pandemic levels. The analysis was posted as a preprint on the medRxiv server and has not yet been peer reviewed.

Source: Nature

https://www.nature.com/articles/d41586-021-03455-w

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!